Orchestra BioMed amends registration rights agreement, delaying S-1 amendment and effectiveness deadlines

Orchestra BioMed Holdings, Inc.

Obligation to amend S-1 deferred to earlier of April 1, 2024 or 15 business days after filing 2023 10-K.
Effectiveness deadline pushed to 90 days after filing first amendment or 10 business days after SEC clearance.
Amendment involves Medtronic affiliate Covidien Group S.à.r.l. and other investors.
Replaces the prior amended registration rights agreement from January 2023.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Orchestra BioMed Holdings, Inc. amended Second Amended and Restated Registration Rights and Lock-Up Agreement with Covidien Group S.à.r.l. valued at Delayed obligation to amend registration statement and cause effectiveness (effective 2023-11-21).

Action: amendment
Counterparty: Covidien Group S.à.r.l.
Value: Delayed obligation to amend registration statement and cause effectiveness
Effective: 2023-11-21

Exact text from the filing

On November 21, 2023, Orchestra BioMed Holdings, Inc. (the “Company”) entered into a Second Amended and Restated Registration Rights and Lock-Up Agreement with certain investors named therein (the “Amended Agreement”), which amended and restated the Amended and Restated Registration Rights and Lock-Up Agreement, dated January 26, 2023 (the “Original Agreement”).

View on SEC.gov

623 material agreements filed in the last 30 days. Browse all material agreements →

Orchestra BioMed Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-121331

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.